{
    "clinical_study": {
        "@rank": "151464", 
        "arm_group": {
            "arm_group_label": "Fractionated Stereotactic Radiosurgery", 
            "arm_group_type": "Other", 
            "description": "24 to 36 Gy in 3 fractions (8-12 Gy/fx)."
        }, 
        "brief_summary": {
            "textblock": "This is a research  trial that seeks to break up the total radiation dose into multiple\n      smaller radiation treatments, termed fractionated stereotactic radiosurgery (FSRS) which may\n      make the treatment feasible. Fractionated sterotatcic radiation, the risks of FSRS, and\n      possible costs will be described later in this document.  This clinical trial is for people\n      who have had no prior whole brain radiation."
        }, 
        "brief_title": "Fractionated Stereotactic Radiosurgery for Large Brain Metastases", 
        "condition": "Large Brain Mets", 
        "condition_browse": {
            "mesh_term": "Neoplasm Metastasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female patients \u2265 18 years of age\n\n          -  A life expectancy of at least 12 weeks with a Karnofsky performance status of at\n             least 70 (Appendix II)\n\n          -  The target lesion(s) can be accurately measured in at least one dimension according\n             to RECIST\n\n          -  No prior radiotherapy to the brain\n\n          -  Previous or concurrent systemic or targeted chemotherapy is allowed.\n\n          -  Patients must have an extra-cranial primary tumor diagnosis\n\n          -  Patients will have no more than 3 distinct lesions within the brain.\n\n          -  At least 1 lesion must be a minimum of 3cm in greatest dimension, no larger than 5cm\n             which will be treatable by fractionated stereotactic radiosurgery\n\n          -  The additional lesions will each be treated with single fraction stereotactic\n             radiosurgery\n\n          -  Patient may be on steroids or anti-epileptics\n\n          -  Must be aware of the neoplastic nature of his/her disease and willingly provide\n             written, informed consent after being informed of the procedure to be followed, the\n             experimental nature of the therapy, alternatives, potential benefits, side-effects,\n             risks and discomforts\n\n          -  Patients do not need a histologically proven diagnosis of brain mets\n\n        Exclusion Criteria:\n\n          -  Symptomatic patients in need of surgery to the \"target\" lesion\n\n          -  Four or more newly-diagnosed lesions\n\n          -  Prior surgical resection of targeted tumor\n\n          -  Prior WBRT\n\n          -  Primary brain tumor\n\n          -  Pregnant or breast-feeding patients\n\n          -  Primary tumor histology of lymphoma, leukemia, multiple myeloma or germ cell tumor"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02054689", 
            "org_study_id": "11-091"
        }, 
        "intervention": {
            "arm_group_label": "Fractionated Stereotactic Radiosurgery", 
            "description": "SRS SBRT CyberKnife Trilogy True Beam Radiosurgery", 
            "intervention_name": "Fractionated Stereotactic Radiosurgery", 
            "intervention_type": "Radiation", 
            "other_name": [
                "SRS", 
                "SBRT", 
                "CyberKnife", 
                "Trilogy", 
                "True Beam", 
                "Radiosurgery"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 31, 2014", 
        "location": {
            "contact": {
                "email": "holevakd@upmc.edu", 
                "last_name": "Karen D Holeva, BS", 
                "phone": "412-623-1275"
            }, 
            "contact_backup": {
                "email": "herond2@upmc.edu", 
                "last_name": "Dwight E Heron, MD", 
                "phone": "412-623-6720"
            }, 
            "facility": {
                "address": {
                    "city": "Pittsburgh", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "15232"
                }, 
                "name": "UPMC Shadyside Radiation Oncology"
            }, 
            "investigator": [
                {
                    "last_name": "Steven Burton, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "David A Clump, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "John Flickinger, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Johnathan Engh, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Nduka Amankulor, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Dwight E Heron, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "PHASE I STUDY OF FRACTIONATED STEREOTACTIC RADIOSURGERY FOR LARGE BRAIN METASTASES", 
        "overall_contact": {
            "email": "holevakd@upmc.edu", 
            "last_name": "Karen D Holeva, BS", 
            "phone": "412-623-1275"
        }, 
        "overall_official": {
            "affiliation": "University of Pittsburgh", 
            "last_name": "Dwight E Heron, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Measured by any patients toxicities Performance status Quality of life", 
            "measure": "Determing the maximum tolerated dose (MTD) and safety of fractionated SRS when treating brain metastases", 
            "safety_issue": "Yes", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02054689"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Pittsburgh", 
            "investigator_full_name": "Dwight Heron", 
            "investigator_title": "Vice Chairman of Clinical Affairs", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Measured by MRI", 
            "measure": "Local control of the disease", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "source": "University of Pittsburgh", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Pittsburgh", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}